Search research articles
Contact Us
Filters
Showing results (191-200 of 287) with videos related to
Page
of 29
Sort By:
JAMA Oncology
|
August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability
Matthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
The Journal of Urology
|
August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS
James T Kearns, Anna V Faino, Jeanette M Schenk, et al.
European Urology
|
February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes
Matthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget
|
February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer
Debashis Sahoo, Wei Wei, Heidi Auman, et al.
Urology Practice
|
May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort
Adrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Nutrition and Cancer
|
November 7, 2022
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study
Jeannette M Schenk, Menghan Liu, Marian L Neuhouser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
John T Wei, Ziding Feng, Alan W Partin, et al.
The Journal of Urology
|
May 10, 2022
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions
James A Eastham, Gregory B Auffenberg, Daniel A Barocas, et al.
The Journal of Urology
|
May 10, 2022
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
James A Eastham, Gregory B Auffenberg, Daniel A Barocas, et al.
European Urology Focus
|
September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Tamara L Lotan, Wei Wei, Carlos L Morais, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 287) with videos related to
Sort By:
Page
of 29
JAMA Oncology
|
August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability
Matthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
The Journal of Urology
|
August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS
James T Kearns, Anna V Faino, Jeanette M Schenk, et al.
European Urology
|
February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes
Matthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget
|
February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer
Debashis Sahoo, Wei Wei, Heidi Auman, et al.
Urology Practice
|
May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort
Adrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Nutrition and Cancer
|
November 7, 2022
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study
Jeannette M Schenk, Menghan Liu, Marian L Neuhouser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
John T Wei, Ziding Feng, Alan W Partin, et al.
The Journal of Urology
|
May 10, 2022
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions
James A Eastham, Gregory B Auffenberg, Daniel A Barocas, et al.
The Journal of Urology
|
May 10, 2022
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
James A Eastham, Gregory B Auffenberg, Daniel A Barocas, et al.
European Urology Focus
|
September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Tamara L Lotan, Wei Wei, Carlos L Morais, et al.
Page
of 29